Vir Biotechnology, Inc., "Vir Biotechnology Identifies Two Antibodies That Bind to The Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2" (press release, Exhibit 99.1 to Form 8-K, Feb. 12, 2020)

Summary

Vir Biotechnology press release of February 12, 2020 (Exhibit 99.1) announcing that it has identified two monoclonal antibodies that bind to SARS-CoV-2, previously known as 2019-nCoV, which were first found because they bind and neutralize the original SARS-CoV. The antibodies target the spike protein in the region the virus uses to enter cells through the receptor ACE2. They come from an existing library of 20 fully human antibodies against related coronaviruses. Chief executive George Scangos says the company is assessing neutralization with a pseudo-virus and working with international partners on the live virus. The company says it is exploring collaborations with other companies and government agencies, including on manufacturing capacity.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

EX-99.1 2 d880055dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Vir Biotechnology Identifies Two Antibodies That Bind to The Spike Protein of

2019-nCoV, Newly Named as SARS-CoV-2

SAN FRANCISCO – February 12, 2020 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on
immune approaches to treating and preventing serious infectious diseases, today announced that it has identified two monoclonal antibodies (mAbs) that bind to SARS-CoV-2 (previously known as “2019-nCoV”), which were originally found because they bind and neutralize the original SARS-CoV. The antibodies target
the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2. Infection with SARS-CoV-2 causes the newly named disease, Covid-19.

“We are in the
process of assessing neutralization with a pseudo-virus,” said George Scangos, Ph.D., CEO of Vir. “In addition, we are working with international partners to assess the capacity of these antibodies to neutralize the live virus, SARS-CoV-2.”

The company is moving ahead with research to determine if its
antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2. To that end, the company is
exploring collaborations with a number of other companies and governmental agencies. Amongst these are specific efforts at accessing manufacturing capacity globally.

“We are pleased that, using the same platform that was used to isolate mAb114 which has proven to be active against Ebola, we have quickly identified
antibodies with potential biological activity against SARS-CoV-2,” said Herbert “Skip” Virgin, M.D., Ph.D., Chief Scientific Officer, Vir. “We are
working as rapidly as possible and look forward to sharing more information as we have it.”

Vir identified these antibodies from an existing library
of 20 fully human antibodies that bind and neutralize related coronaviruses, such as SARS-CoV and coronaviruses that infect animals. This library was built through a robust method for capitalizing on unusually successful immune responses naturally
occurring in people who are protected from, or have recovered from, infectious diseases, including those caused by rapidly evolving and/or previously untreatable pathogens.

Antibody-based therapies are different from vaccines and have distinct attributes that may make them
potentially valuable, particularly in pandemic settings:

• | Antibodies can be therapeutic and prophylactic, meaning they can be used as a treatment for people who have been
infected and can also protect people who have been, or may be, exposed to infection.
• | Whereas a vaccine requires an individual to make an immune response, which can take weeks and be insufficient, an
antibody provides the immune response, which can be effective within hours of injection and is not dependent upon the individual making an immune response to the pathogen.
• | Antibodies can be engineered to have an extended half-life of several months or more.

Vir is investigating other approaches to identify additional potential therapies for SARS-CoV-2. In addition to testing these two antibodies, the company is also exploring the isolation of new antibodies specific for this virus using its antibody
technology platform. These efforts may allow additional approaches to address this rapidly emerging public health epidemic.

About Vir’s Antibody
Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or
have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and
immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in
the Democratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious
infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product
candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.

Forward-Looking Statements

This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements
are based on Vir’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include statements regarding the company’s efforts to

neutralize the SARS-CoV-2 virus and identify additional potential therapies for SARS-CoV-2, and its ability to address the emerging public health epidemic. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data
observed during preclinical or clinical studies, challenges in neutralizing SARS-CoV-2, difficulty in collaborating with other companies or government agencies, and
challenges in accessing manufacturing capacity within China. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the
U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in
expectations, even as new information becomes available.

Contact:

Vir Biotechnology, Inc.

Investors

Neera Ravindran, MD

Head of Investor Relations &
Strategic Communications

nravindran@vir.bio

+1-415-506-5256

Media

Lindy Devereux

Scient PR

lindy@scientpr.com

+1-646-515-5730

File and source

File

SEC_VIR_8-K_filed2020-02-12_0001193125-20-033376_EX-99.1.htm

Size

13,500 bytes

SHA-256

abe83b41aa17355166d7e73d1d9c9e6be6a007ffe29f0f35aaf83ea7d7513d2c

Our copy

SEC_VIR_8-K_filed2020-02-12_0001193125-20-033376_EX-99.1.htm

Original

www.sec.gov